drugset
drugset / Trial / NCT02756624

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

NCT02756624 ↗

Phase 3 Completed 516 enrolled Nicox Ophthalmics, Inc. ORA, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution

Timeline

Start
2016-04
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified 0.24 % Other

Indications

No indication recorded.